Document Detail

APAP impact on metabolic syndrome in obstructive sleep apnea patients.
MedLine Citation:
PMID:  20862557     Owner:  NLM     Status:  In-Data-Review    
PURPOSE: Prevalence of metabolic syndrome (MS) in obstructive sleep apnea (OSA) patients is high. The effect of autoadjusting positive airway pressure (APAP) on MS remains unclear. This study aimed to determine the prevalence of MS in OSA patients before and 6 months after APAP, and to identify potential determinants of metabolic status change.
METHODS: Seventy-four male patients with moderate to severe OSA were enrolled. MS diagnosis was established according to the National Cholesterol Education Program/Adult Treatment Panel III. APAP was prescribed to all patients.
RESULTS: In the studied population, mean age was 55.9 years (SD 10.7 years), median body mass index (BMI), Epworth sleepiness scale (ESS), and respiratory disturbance index (RDI) were 33.4 kg/m(2) (interquartile range (IQR) 8.4 kg/m(2)), 12.0 (IQR 8.0), and 46.9/h (IQR 33.6/h), respectively. Prevalence of MS before and 6 months after APAP was 63.5% and 47.3%, respectively, and this difference was statistically significant (p = 0.004). In the subgroup of patients with MS at baseline (n = 47), 14 did not present MS after APAP. In these patients, a significant negative association with RDI (p = 0.016) and a positive association with percent of total days of usage (p = 0.014) were found. Blood pressure (p = 0.018) and serum triglycerides (p = 0.001) had a statistically significant reduction during this period. In patients that still had MS, 22.2% presented a reduction of the number of MS criteria.
CONCLUSIONS: After 6 months, APAP reduced the prevalence of MS, mainly in patients with less severe OSA and with a better therapeutic compliance. Blood pressure and serum triglycerides reduction contributed to this metabolic status change.
Patrícia Caetano Mota; Marta Drummond; João Carlos Winck; Ana Cristina Santos; João Almeida; José Agostinho Marques
Related Documents :
264157 - Fluctuation of plasma cortisol levels in multiple sclerosis.
7560007 - In vitro cytokine, scd23 and igg secretion in multiple sclerosis.
2106327 - Prolonged improvement of raynaud's phenomenon and scleroderma after recombinant tissue ...
8105377 - Neuromuscular transmission in amyotrophic lateral sclerosis.
2571387 - Haematological side-effects of sulphasalazine in inflammatory arthritis.
10888207 - Left ventricular aneurysm without coronary artery disease, incidence and clinical featu...
Publication Detail:
Type:  Journal Article     Date:  2010-09-24
Journal Detail:
Title:  Sleep & breathing = Schlaf & Atmung     Volume:  15     ISSN:  1522-1709     ISO Abbreviation:  Sleep Breath     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9804161     Medline TA:  Sleep Breath     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  665-72     Citation Subset:  IM    
Department of Pulmonology, Hospital de São João, Alameda Professor Hernâni Monteiro, 4200-319, Porto, Portugal,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Analyzing strange sounds during night.
Next Document:  Net anthropogenic nitrogen accumulation in the Beijing metropolitan region.